Drug Trial Radar · NCT06668103
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
Last checked: Nov 19, 2026Latest source record: Dec 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
54
Planned (sponsor's estimate)
Start
Nov 25, 2024
Primary completion
Dec 30, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Abbisko Therapeutics Co, LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally advanced or metastatic NSCLC.
Conditions
- Non-Small Cell Lung Cancer With EGFR Mutation
Interventions
ABSK043 in combination with FirmonertinibDrug
Two potential dose levels :400 mg twice daily (BID) and 800 mg BID) of ABSK043 are prespecified and firmonertinib will be administered orally at a fixed dose of 80 mg once daily (QD). Patients in dose escalation cohort will receive the ABSK043, 400 mg BID and firmonertinib 80 mg QD as the starting dose for the combination therapy. Patients in dose confirmation cohort and dose expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity of the combination therapy. After Cycle 1, patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of DLTTime frame: At the end of Cycle 1 (each cycle is 21 days)
- AEsTime frame: From the time the patient signs the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of furmonertinib mesylate, whichever occurs first, up to 30 months.
- SAEsTime frame: From the time patients sign the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of furmonertinib mesylate, whichever occurs first, up to 30 months.
- AESIsTime frame: From the time patients sign the informed consent form throughout the study and up to 90 days after the last dose of ABSK043 or 30 days after the last dose of furmonertinib mesylate, whichever occurs first, up to 30 months.
- PFS rate at 12 monthTime frame: From the time patients receive the first dose of study drug to 12 months,assessed up to 30 months.
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Hanhui Cancer Hospital
Hefei, Anhui, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Union Hospital Tongji Medical College Huzhong University of Science and Techology
Wuhan, Hubei, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.